QUILT-3.013: Study of Ad5 [E1-, E2b-]-HER2/Neu Vaccine (ETBX-021) in Subjects With Unresectable Locally Advanced or Metastatic HER2-Expressing Breast Cancer
Clinical trial NCT02751528 · TERMINATED
Trial details
- NCT number
- NCT02751528
- Sponsor
- NantBioScience, Inc.
- Status
- TERMINATED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2017-03-04
- Primary completion
- 2018-08-16
- Enrollment
- 3
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.